Tavo Biotherapeutics Inc. has successfully closed a $17 million series A financing, with the proceeds directed to advancing the company’s pipeline of innovative therapies targeting glaucoma and retinal disease.
Cell replacement therapy is currently being investigated to restore the retinal pigment epithelium (RPE) layer and treat vision decline due to dry age-related macular degeneration (AMD). The Neural Stem Cell Institute and collaborating institutions developed an approach to RPE replacement using an adult RPE stem cell source derived from the RPE layer of donated cadaver eyes.
Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders.
Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders.
Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders.
As advances are made by bustling drug developers at work in the Wingless-related integration site (Wnt) pathway, other research is yielding new discoveries as well. Among the closely watched industry players in Wnt are Boehringer Ingelheim GmbH, Merck & Co. Inc., and Surrozen Inc.
Biogen Inc. hardly blinked at the competition faced by Apellis Pharmaceuticals Inc. as the two companies sealed a deal whereby the former has agreed to acquire all outstanding shares of the latter for $41 each, or about $5.6 billion.
Researchers from Harvard Medical School and Spark Therapeutics Inc. tested subretinal NRF2 gene therapy in dry AMD models to investigate whether it could relieve oxidative stress and inflammation.
Fannin Partners LLC has been awarded a $300,000 phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) to advance a first-in-class, non-VEGF-targeted therapeutic for wet age-related macular degeneration (AMD) in patients not responding to anti-VEGF therapies.
